Sign in Subscribe
Chief executive officers

Conexeu Sciences Appoints Miles D. Harrison as President & Chief Executive Officer

Strategic Insights

— 2 min read

Conexeu Sciences Inc. has announced the appointment of Miles D. Harrison as its new President & Chief Executive Officer, effective immediately. Harrison will lead the company's next phase of growth, advancing its groundbreaking collagen platform for human and animal health. He will focus on scientific validation, strategic partnerships, and a unified brand strategy across wound care, dental, and aesthetics.

Key Takeaways:

  • Miles D. Harrison brings over two decades of leadership experience in scaling category-defining healthcare and aesthetics businesses, most recently as President and CEO, North America, at Galderma.
  • Harrison will lead Conexeu's next phase of growth, advancing its first-in-class collagen platform for human and animal health, which is poised to revolutionize regenerative medicine.
  • The company's patented CXU™ platform represents a next-generation liquid extracellular matrix, providing a complex and bioactive scaffold for cells to organize healing, not scarring.
  • Conexeu's portfolio includes Ten Minute Tissue™, a liquid dermal extracellular matrix (ECM) that remains fluid at room temperature and gels at body temperature, promoting cell migration, proliferation, differentiation, and new tissue formation.
  • Harrison has proven experience in building high-performance organizations and creating shareholder value, having served as President and CEO at Galderma and Co-Founder and CEO of Novaestiq Corp.
  • Conexeu's platform has transformative potential across multi-billion-dollar markets, with patents filed across the U.S., E.U., Japan, and Australia, and additional filings pending globally.
  • Harrison will work closely with the company's existing leadership team, including Dr. Claudia Chavez-Munoz, Co-Founder and Chief Science Officer, to advance Conexeu's mission and vision.
  • The company has reported significant progress in clinical studies, with Ten Minute Tissue™ accelerating healing while reducing inflammation and non-fibrotic scarring.

Statistics:

  • Conexeu Sciences was founded in late 2022 and has since established itself as a leading player in the regenerative medicine space.
  • The company's patented CXU™ platform is poised to revolutionize human and animal health, with transformative potential across multi-billion-dollar markets.
  • Ten Minute Tissue™ has been clinically proven in pilot studies to accelerate healing while reducing inflammation and non-fibrotic scarring.
  • Conexeu's pipeline includes multiple products in development, with the potential to address a wide range of applications, including wound care, dental, and aesthetics.

Sources:

  • Conexeu Sciences Inc. news release, dated November 3, 2025
  • Galderma corporate website, noting Miles Harrison's experience as President and CEO, North America
  • Novaestiq Corp. website, highlighting Harrison's role as Co-Founder and CEO
  • Castle Biosciences, Inc. (NASDAQ: CSTL) website, listing Harrison as a member of the Board of Directors
  • Conexeu Sciences corporate website, providing information on the company's history, mission, and vision.

Read more